Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year

Reports Q3 revenue $0, consensus $33.33M. Cash, cash equivalents and short-term investments as of September 30, 2025, were $162.6M vs. $47.2M as of December 31, 2024. Cash is anticipated to fund operations into 2028 based on current plans. “Q3 was marked by executional focus, and we remain on track with our planned IND filings for HWK-007 and HWK-016 by the end of the year. We continue to deploy capital efficiently, maintaining strong financial discipline as we prepare to enter the clinic and deliver potentially value-creating milestones,” said Dave Lennon, CEO. “I’m proud of our role in adding to the scientific understanding of PTK7 with the data we presented at AACR-NCI-EORTC. Confirming PTK7 as the third most highly expressed tumor marker among clinically validated and emerging ADC targets, these data underscore the tremendous opportunity we have with our first ADC candidate, HWK-007, to make a difference for the nearly 750,000 patients in the US with PTK7-expressing cancers.”